Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer

In this podcast episode, listen to lung cancer experts Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer audience questions from a live CCO webinar on biomarker testing to guide selection of targeted and immune checkpoint inhibitor–based therapies for advanced NSCLC.
Jamie E. Chaft, MD
Stephen V. Liu, MD
Nathan Pennell, MD, PhD
Released: May 19, 2021

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:

  • Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC
  • Incorporating newly approved immunotherapies into practice
  • Evolving guidelines and recommendations for biomarker testing
  • RNA- vs DNA-based next-generation sequencing
  • Interpretation of NGS results
  • Use of frontline TKI therapy for patients with CNS metastases
  • Future role of KRAS inhibitors in the treatment of advanced NSCLC
  • Improving rates of biomarker testing in lung cancer

Presenters:

Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen V. Liu, MD
Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Lilly
Regeneron Pharmaceuticals, Inc & Sanofi Genzyme

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

On-demand webcast from CCO where clinical experts discuss how to optimally integrate the latest clinical data on predictive biomarkers to guide treatment decisions in advanced NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO
Program Director
Stephen V. Liu, MD Lecia V. Sequist, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 26, 2021 Expired: July 25, 2022

Downloadable slideset of FcRn pathway inhibition in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of BTK inhibitors in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of an expert’s overview of emerging therapies for patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue